{"id":"NCT01217307","sponsor":"University Medical Center Groningen","briefTitle":"Metformin to Reduce Heart Failure After Myocardial Infarction","officialTitle":"Metabolic Modulation With Metformin to Reduce Heart Failure After Acute Myocardial Infarction: Glycometabolic Intervention as Adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III): a Randomized Controlled Trial.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2011-01","primaryCompletion":"2013-10","completion":"2015-10","firstPosted":"2010-10-08","resultsPosted":"2018-01-30","lastUpdate":"2018-01-30"},"enrollment":380,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["ST Elevation Myocardial Infarction (STEMI)","Coronary Artery Disease","Heart Failure","Diabetes"],"interventions":[{"type":"DRUG","name":"Metformin","otherNames":["Glucophage"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Metformin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The investigators will evaluate the effect of metformin therapy during 4 months in non-diabetic patients following ST-elevation myocardial infarction on left ventricular ejection fraction as measured with cardiac magnetic resonance imaging, compared to placebo.","primaryOutcome":{"measure":"Improvement in Left Ventricular Ejection Fraction","timeFrame":"4 months","effectByArm":[{"arm":"Metformin","deltaMin":53.1,"sd":null},{"arm":"Placebo","deltaMin":54.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":9},"locations":{"siteCount":1,"countries":["Netherlands"]},"refs":{"pmids":["36690932","34593124","28755285","28100626","26808474","26688733","24687169","22968678"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":191},"commonTop":["Non-target lesion revascularization","Hospitalization for chest pain","CABG"]}}